Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$1.44 - $2.73 $14.9 Million - $28.2 Million
-10,317,698 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$2.63 - $3.67 $3.99 Million - $5.57 Million
-1,516,969 Reduced 12.82%
10,317,698 $27.2 Million
Q1 2021

May 17, 2021

SELL
$2.82 - $5.6 $1.78 Million - $3.54 Million
-631,581 Reduced 5.07%
11,834,667 $42.6 Million
Q4 2020

Feb 16, 2021

BUY
$2.09 - $3.09 $168,583 - $249,245
80,662 Added 0.65%
12,466,248 $31.4 Million
Q3 2020

Nov 16, 2020

SELL
$2.39 - $3.43 $559,604 - $803,113
-234,144 Reduced 1.86%
12,385,586 $31.2 Million
Q2 2020

Aug 14, 2020

SELL
$2.2 - $3.71 $522,071 - $880,401
-237,305 Reduced 1.85%
12,619,730 $41.4 Million
Q1 2020

May 15, 2020

BUY
$1.9 - $4.98 $233,320 - $611,544
122,800 Added 0.96%
12,857,035 $31.5 Million
Q4 2019

Feb 14, 2020

SELL
$3.95 - $5.35 $983,198 - $1.33 Million
-248,911 Reduced 1.92%
12,734,235 $60.1 Million
Q3 2019

Nov 14, 2019

BUY
$4.13 - $6.94 $15.5 Million - $26 Million
3,743,996 Added 40.52%
12,983,146 $55.6 Million
Q1 2019

May 15, 2019

SELL
$2.0 - $4.4 $51,100 - $112,420
-25,550 Reduced 0.28%
9,239,150 $35.6 Million
Q4 2018

Feb 14, 2019

BUY
$1.61 - $3.62 $7.16 Million - $16.1 Million
4,447,154 Added 92.31%
9,264,700 $16.6 Million
Q3 2018

Nov 14, 2018

SELL
$2.26 - $3.27 $224,022 - $324,138
-99,125 Reduced 2.02%
4,817,546 $15.4 Million
Q2 2018

Aug 14, 2018

SELL
$3.02 - $4.94 $366,250 - $599,098
-121,275 Reduced 2.41%
4,916,671 $14.8 Million
Q1 2018

May 15, 2018

SELL
$3.46 - $5.14 $160,198 - $237,981
-46,300 Reduced 0.91%
5,037,946 $19.7 Million
Q4 2017

Feb 14, 2018

BUY
$4.0 - $6.54 $903,560 - $1.48 Million
225,890 Added 4.65%
5,084,246 $21 Million
Q3 2017

Nov 14, 2017

BUY
$4.99 - $6.57 $24.2 Million - $31.9 Million
4,858,356
4,858,356 $29.8 Million

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $236M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track Bill Miller's Portfolio

Track Bill Miller Portfolio

Follow Bill Miller (Miller Value Partners, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Miller Value Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Miller Value Partners, LLC and Bill Miller with notifications on news.